Osteoporosis in the age of COVID-19

Girgis, C. M.; Clifton-Bligh, R. J.

Affiliations

¹Faculty of Medicine and Health, University of Sydney, Sydney, Australia

²Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia

³Department of Endocrinology and Diabetes, Westmead Hospital, Sydney, Australia

Abstract and keywords

As the world grapples with the crisis of COVID-19, established economies and healthcare systems have been brought to their knees. Tough decisions regarding redirection of resources away from the management of conditions deemed “nonessential” are being made. How can we balance urgent resourcing of our acute crisis while not abandoning the real need of patients with osteoporosis? This article offers a few practical solutions.

Keywords: Osteoporosis; COVID-19; Fracture; Bisphosphonate; Denosumab; Bone mineral density

Links

DOI: 10.1007/s00198-020-05413-0

PubMed: 32346775

WoS: 000529480200002

History

Received: 2020-03-26

Accepted: 2020-04-06

Online: 2020-04-28

Cited Works (6)

Year	Entry
2016	Black DM, Rosen CJ. Postmenopausal osteoporosis. NEJM. January 21, 2016;374(3):254-262.
2019	Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. January 2019;30(1):79-92.
2018	Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res. February 2018;33(2):211-220.
2017	Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. December 2017;105:11-17.
2006	Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. December 2006;17(12):1726-1733.
2017	Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. June 2017;32(6):1291-1296.

Cited By (4)

Year	Entry
2022	Kocijan R, Stockinger T, Haschka J, Reichardt B, Resch H, Zwerina J, Behanova M. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic. Bone. September 2022;162:116477.
2021	McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Vandenput L, Liu E, Kanis JA. Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporos Int. January 2021;32(1):39-46.
2021	Ibrahimagić OĆ, Vujadinović A, Ercegović Z, Kunić S, Smajlović D, Dostović Z. Comment on an article: "osteoporosis in the age of COVID-19 patients". Osteoporos Int. April 2021;32(4):783-784.
2021	Girgis CM, Clifton-Bligh RJ. Reply to comment on "Osteoporosis in the age of COVID-19". Osteoporos Int. April 2021;32(4):795-795.